Literature DB >> 11684721

Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival.

A Hara1, M Saegusa, T Mikami, I Okayasu.   

Abstract

AIMS: Although frequent reduction or loss of DCC (deleted in colorectal carcinomas) has been demonstrated in gliomas, the association with cell kinetics and survival is still unclear.
METHODS: A total of 119 astrocytomas, comprising 39 grade IV, 36 grade III, and 44 low grade tumours, were immunohistochemically investigated, along with 26 normal adult brain samples and two fetal brains. The results were compared with p53 abnormalities, Ki-67 labelling index (LI), mitotic index (MI), apoptotic index (AI), and survival.
RESULTS: In normal adult and fetal brain tissues, DCC expression was detected in mature and terminally differentiated neuronal cells but not glial elements. In astrocytomas, whereas DCC expression was still clearly shown with low grade malignancy, DCC scores were significantly decreased in high histological grade malignancy, along with an increase in cell kinetics determined by AI, MI, and Ki-67 LI values. In addition, p53 LI values were significantly increased, although a direct link between DCC scores and p53 LI values was not evident. Univariate analysis revealed that high DCC scores and low p53 LI values were closely related to a favourable outcome for astrocytoma, although only the AI was an independent prognostic factor.
CONCLUSIONS: The loss of DCC expression may be closely related to changes in cell kinetics and tumour phenotype in astrocytomas, independent of p53 abnormalities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684721      PMCID: PMC1731311          DOI: 10.1136/jcp.54.11.860

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  30 in total

1.  Frequent loss of heterozygosity at the DCC locus in gastric cancer.

Authors:  S Uchino; H Tsuda; M Noguchi; J Yokota; M Terada; T Saito; M Kobayashi; T Sugimura; S Hirohashi
Journal:  Cancer Res       Date:  1992-06-01       Impact factor: 12.701

2.  Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases.

Authors:  A Korshunov; A Golanov; R Sycheva; I Pronin
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  The significance of the expression of tumor suppressor gene DCC in human gliomas.

Authors:  K Nakatani; N Yoshimi; H Mori; H Sakai; J Shinoda; T Andoh; N Sakai
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

4.  Alterations in the deleted in colorectal carcinoma gene in human primary leukemia.

Authors:  K Miyake; K Inokuchi; K Dan; T Nomura
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

5.  Identification of a chromosome 18q gene that is altered in colorectal cancers.

Authors:  E R Fearon; K R Cho; J M Nigro; S E Kern; J W Simons; J M Ruppert; S R Hamilton; A C Preisinger; G Thomas; K W Kinzler
Journal:  Science       Date:  1990-01-05       Impact factor: 47.728

6.  Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers.

Authors:  Y Huang; R F Boynton; P L Blount; R J Silverstein; J Yin; Y Tong; T K McDaniel; C Newkirk; J H Resau; R Sridhara; B J Reid; S J Meltzer
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

7.  Expression of the tumor suppressor gene DCC in human gliomas.

Authors:  A C Scheck; S W Coons
Journal:  Cancer Res       Date:  1993-12-01       Impact factor: 12.701

8.  Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas.

Authors:  X Gao; K V Honn; D Grignon; W Sakr; Y Q Chen
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

9.  Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.

Authors:  E Jaros; R H Perry; L Adam; P J Kelly; P J Crawford; R M Kalbag; A D Mendelow; R P Sengupta; A D Pearson
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

10.  Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer.

Authors:  A M Thompson; R G Morris; M Wallace; A H Wyllie; C M Steel; D C Carter
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more
  6 in total

Review 1.  Apoptotic markers for primary brain tumor prognosis.

Authors:  A E Konstantinidou; P Korkolopoulou; E Patsouris
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

Review 2.  P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature.

Authors:  Georgia Levidou; Elias El-Habr; Angelica A Saetta; Christine Bamias; Klea Katsouyanni; Klea Katsougiannis; Efstratios Patsouris; Penelope Korkolopoulou
Journal:  J Neurooncol       Date:  2010-05-12       Impact factor: 4.130

3.  Immunohistochemical markers for prognosis of anaplastic astrocytomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

4.  Immunohistochemical markers for prognosis of cerebral glioblastomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

5.  Netrin-1 promotes glioma growth by activating NF-κB via UNC5A.

Authors:  Jing-Ying Chen; Xiao-Xiao He; Chi Ma; Xin-Min Wu; Xi-Lin Wan; Zhen-Kai Xing; Qing-Qing Pei; Xian-Ping Dong; Dong-Xu Liu; Wen-Cheng Xiong; Xiao-Juan Zhu
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

6.  Microarray Expression Data Identify DCC as a Candidate Gene for Early Meningioma Progression.

Authors:  Hans-Juergen Schulten; Deema Hussein; Fatima Al-Adwani; Sajjad Karim; Jaudah Al-Maghrabi; Mona Al-Sharif; Awatif Jamal; Fahad Al-Ghamdi; Saleh S Baeesa; Mohammed Bangash; Adeel Chaudhary; Mohammed Al-Qahtani
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.